Dr Nicholas K Christoforidis MD, MSc, FRCOG
Consultant Obstetrician & Gynaecologist, Embryolab Clinical & Scientific Director
Nikos Christoforidis is a gynecologist specializing in infertility analysis and assisted reproductive technology.
The ARTEMIS study findings were presented by Dr. Nicholas Christoforidis MD, MSc, FRCOG, Consultant Obstetrician-Gynecologist, Scientific & Clinical Director of Embryolab Fertility Clinic, during a recent scientific meeting* which was held at the Embryolab Fertility Clinic, on February 21.
” Dr. Christoforidis, emphasized that this is actually about a pioneering study in Greece, which highlights the positive results of the use of follitropin A in IVF, significantly contributing to the treatment of infertility, supporting many couples to create their families.
The ARTEMIS study was carried out by the pharmaceutical company MERCK with the participation of 350 women and studied a total of 430 IVF cycles, using follitropin A in ovarian stimulation protocols. The study collected data from daily clinical practice with the aim of incorporating costs of examinations and hospitalization, including the delivery of a baby.
Mr. Dimitris Sakellariou, Medical Manager of Fertility/ CM&E Merck Greece in Greece and Cyprus, stated that the results highlight the positive cost-effectiveness of using follitropin A in IVF, helping couples to have babies and create their family.
The ARTEMIS study findings were also published in the scientific journal Current Medical Research and Opinion. Embryolab Fertility Clinic actively participated in the study, which aimed to determine the probability of having a healthy child after IVF treatment with follitropin A, while at the same time examining in detail the relationship
cost effectiveness of the use of follitropin A.
